Skip to content

AbbVie / Allergan: The Company Behind Botox

AbbVie is the company behind Botox and Botox Cosmetic. Their U.S. prescribing information names AbbVie Inc. as the manufacturer (BOTOX prescribing information — AbbVie 🔗; BOTOX Cosmetic prescribing information — AbbVie 🔗).

Allergan built the Botox franchise before AbbVie completed its acquisition of Allergan on May 8, 2020 🔗. Allergan Aesthetics is AbbVie’s aesthetics business, whose portfolio includes Botox Cosmetic. These names describe related corporate and product roles, rather than competing Botox manufacturers (About Allergan Aesthetics 🔗).

Common questionShort answer
Who manufactures Botox?The U.S. BOTOX and BOTOX Cosmetic prescribing information names AbbVie Inc. as the manufacturer. Allergan is the historical company associated with the franchise.
Who owns Botox?AbbVie acquired Allergan in 2020 and owns the Botox franchise. Allergan Aesthetics is its aesthetics business, including Botox Cosmetic.
Where is Botox manufactured?Westport, County Mayo, Ireland is a documented Botox production site. The site’s 2024 environmental report records Botox manufacturing; the U.S. label’s manufacturer address is a separate fact.
Is Allergan the same as AbbVie?AbbVie acquired Allergan; the names are not interchangeable. Allergan can refer to the historical company, a legal entity, or the Allergan Aesthetics business, depending on the document.
Is Botox Cosmetic the same as therapeutic Botox?Both use onabotulinumtoxinA, but Botox Cosmetic and therapeutic Botox have different U.S. label contexts, indications, dosing language, and reader-use cases.
Is trenibotulinumtoxinE a new Botox?No. Boey is a separate type E medicine with regional approvals and commercialization, not a renamed Botox or Botox Cosmetic product.
Is Botox Cosmetic FDA approved for masseter muscle prominence?Allergan Aesthetics announced FDA acceptance of the supplemental application on August 4, 2026. This is a review milestone; the current U.S. label lists four other aesthetic indications.
FieldReference point
Official websiteAbbVie 🔗
Public listingNYSE: ABBV (AbbVie Q3 2026 results 🔗)
Parent companyAbbVie 🔗, which acquired Allergan in 2020
U.S. label manufacturerAbbVie Inc. (BOTOX prescribing information 🔗)
Documented Botox production siteWestport, County Mayo, Ireland (2024 site report — Irish EPA 🔗)
Aesthetics businessAllergan Aesthetics 🔗, an AbbVie company
Historical companyAllergan, the company that built the Botox franchise before the acquisition
Core toxin relationshipEstablished type A franchise centered on onabotulinumtoxinA; separate type E product Boey with regional approvals (EMA Boey record 🔗)
Main product nodesBotox, Botox Cosmetic, and Boey / trenibotulinumtoxinE

Who Manufactures Botox: AbbVie, Allergan, Or Allergan Aesthetics?

Section titled “Who Manufactures Botox: AbbVie, Allergan, Or Allergan Aesthetics?”

For the United States, the manufacturer named in both product labels is AbbVie Inc., with a North Chicago, Illinois address. The labels also identify BOTOX as a trademark of Allergan, Inc., an AbbVie company. A manufacturer statement and a trademark statement describe different roles (BOTOX prescribing information — AbbVie 🔗; BOTOX Cosmetic prescribing information — AbbVie 🔗).

Allergan Aesthetics develops, manufactures, and markets an aesthetics portfolio within AbbVie, including Botox Cosmetic. That business identity explains why its name appears prominently on cosmetic-product websites. It does not replace the manufacturer statement in a particular product’s prescribing information (About Allergan Aesthetics 🔗).

The 2020 acquisition brought both Botox Therapeutics and the aesthetics business into AbbVie. Therapeutic Botox therefore should not be described solely through the Allergan Aesthetics business name (AbbVie acquisition announcement 🔗).

Westport, County Mayo, Ireland is a documented Botox manufacturing location. The site’s 2024 Annual Environmental Report, submitted to Ireland’s Environmental Protection Agency, identifies the company as AbbVie trading as Allergan Pharmaceuticals Ireland Unlimited Company. It records Botox manufacture in the site’s Biologics 1 and Biologics 2 plants (2024 Westport Annual Environmental Report — Irish EPA 🔗).

The U.S. label’s North Chicago manufacturer address and the Irish production site answer different questions: which company the label names, and where documented production takes place. A U.S. company address alone does not establish that a product is physically manufactured in the United States.

Botox Is A Brand, Not Every Botulinum Toxin

Section titled “Botox Is A Brand, Not Every Botulinum Toxin”

Botox and Botox Cosmetic contain onabotulinumtoxinA. Their product-specific labeling and potency units do not extend to other botulinum toxin brands (BOTOX prescribing information — AbbVie 🔗). Questions about the manufacturer of Botox have a specific corporate answer; questions about botulinum toxin manufacturers cover a wider industry. The company directory connects other toxin brands with their respective companies.

Botox and Botox Cosmetic share the active ingredient onabotulinumtoxinA, but have distinct U.S. label contexts. Therapeutic Botox prescribing information 🔗 includes chronic migraine, spasticity, cervical dystonia, axillary hyperhidrosis, blepharospasm, strabismus, and bladder-related uses, with indication-specific patient criteria. Botox Cosmetic prescribing information 🔗 lists four adult aesthetic indications: moderate to severe glabellar lines, lateral canthal lines, forehead lines, and platysma bands.

On August 4, 2026, Allergan Aesthetics announced that FDA had accepted a supplemental Biologics License Application, an application to expand an existing product’s approved uses, for Botox Cosmetic in adults with marked to very marked masseter muscle prominence associated with masseter muscle activity. The masseter is a chewing muscle whose prominence can contribute to a wider lower face. Acceptance for review is not approval of this use. The application seeks a fifth U.S. aesthetic indication (AbbVie FDA-acceptance announcement 🔗).

The company’s toxin portfolio also includes Boey, the trenibotulinumtoxinE type E medicine. Health Canada recorded approval in June 2026, and the European Commission granted marketing authorization on July 15, 2026 for a specified adult glabellar-line indication (Health Canada authorization record 🔗; EMA Boey record 🔗).

Commercial introduction is a separate milestone. Health Canada’s Drug Product Database 🔗 records Boey as marketed, with an original market date of October 5, 2026. Boey also appears in AbbVie France’s marketed-product list 🔗, corroborated by VIDAL’s commercialized status 🔗. These records do not establish simultaneous availability throughout Europe.

Boey is not FDA approved. AbbVie reported a manufacturing-related Complete Response Letter on April 23, 2026, meaning the application could not be approved in its submitted form. The company said FDA requested no additional clinical studies (AbbVie U.S. BLA update 🔗). In its October 30, 2026 earnings call, management anticipated resubmission before the end of 2026 and a decision in mid-2027, according to the published AbbVie Q3 transcript — The Motley Fool 🔗. This remains company guidance, not an accepted filing or an FDA-assigned deadline. The U.S. regulatory-status reference tracks the application stage.

The broad visibility of Botox creates a useful reference point for readers entering the field, but it also creates a common misread: a Botox-based assumption should not be applied automatically to another botulinum toxin product.

AbbVie reports Botox Therapeutic within neuroscience and Botox Cosmetic within aesthetics. Its October 30, 2026 earnings release gives the following global net revenues for the quarter ended September 30, 2026 (AbbVie Q3 2026 financial results 🔗):

Reporting lineQ3 2026 global net revenuesReported year-over-year change
Botox Therapeutic$1.080 billion+9.8%
Botox Cosmetic$669 million+4.9%
Total aesthetics portfolio$1.176 billion−1.4%

Botox Cosmetic is included in the aesthetics total; therapeutic Botox is reported separately. The aesthetics total also includes non-toxin products, so it is not a measure of Botox sales alone. Revenue differences describe commercial performance, not clinical superiority, potency, or interchangeability.

PersonRelationship to this company node
Edward J. SchantzBotulinum toxin purification and medical-use research figure upstream of the branded Botox franchise.
Alan B. ScottOculinum / Botox therapeutic-origin figure whose work precedes Allergan’s later Botox franchise development.
Mitchell Brin, M.D.Neurologist and long-running Botox / neurotoxins R&D leader connecting clinical research with Allergan and AbbVie development and licensure.
Jean CarruthersOphthalmologist linked to the Botox Cosmetic glabellar-line pathway and the Carruthers cosmetic-use publication history.
Alastair CarruthersDermatologist linked to the Botox Cosmetic glabellar-line pathway and aesthetic medicine adoption.
David E. I. PyottHistorical Allergan CEO during Botox Cosmetic’s 2002 U.S. approval and the Botox franchise’s major commercial expansion period.
Nicole Mowad-NassarSenior Vice President, AbbVie and President, Global Allergan Aesthetics, leading the global aesthetics portfolio (AbbVie leadership biography 🔗).
Darin J. Messina, Ph.D.Senior Vice President, Head of Aesthetics R&D, named in the Botox Cosmetic masseter-application announcement (AbbVie announcement 🔗).
Carrie StromFormer Global President of Allergan Aesthetics and the launch leader named in AbbVie’s 2020 announcement creating the dedicated aesthetics business.

Botox interpretation should stay tied to current prescribing information. Units are product-specific, approved uses differ by label and country, and the Botox name should not be used as a generic dosing or comparison standard.

Botulinum toxin type A provides the shared serotype context for Botox. Botulinum toxin type E separates trenibotulinumtoxinE’s biology and regional regulatory status from the established franchise. Botulinum toxin explains why products in the same family can still differ in assays, indications, formulation, and safety language.

1. A U.S. Botox label names AbbVie Inc., while a cosmetic-product website uses Allergan Aesthetics. How should these names be understood?
2. Does the North Chicago address in the U.S. manufacturer statement establish that Botox is physically produced in the United States?
3. Does Boey's place in the same portfolio make it another Botox presentation?
4. How should management's planned Boey resubmission and expected decision timing be interpreted?
5. FDA accepts an application to add masseter muscle prominence to Botox Cosmetic's U.S. label. What does that establish?